期刊文献+

奥沙利铂联合卡培他滨治疗晚期胃癌临床效果评价 被引量:6

下载PDF
导出
摘要 目的观察奥沙利铂联合卡培他滨治疗晚期胃癌的临床效果。方法将58例晚期胃癌患者随机分为两组,各29例。对照组在常规对症支持治疗基础上,应用卡培他滨进行化疗;观察组采用奥沙利铂联合卡培他滨进行化疗。两组均以21 d为1个治疗周期,4个周期为1个疗程。治疗结束后,比较两组近期疗效。结果观察组近期临床总有效率为48.3%,高于对照组的20.7%(P<0.05)。结论奥沙利铂联合卡培他滨治疗晚期胃癌的近期疗效显著。
出处 《白求恩医学杂志》 2014年第2期172-173,共2页 Journal of Bethune Medical Science
  • 相关文献

参考文献6

二级参考文献80

  • 1秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:268
  • 2李瑞中,刘汉锋.进展期胃癌的化学药物治疗现状[J].肿瘤学杂志,2006,12(6):504-507. 被引量:21
  • 3胡国勇,胡娟,杨建国,丁岩冰,吴健,肖炜明.卡培他滨联合草酸铂和紫杉醇一线治疗晚期或转移性胃癌[J].咸宁学院学报(医学版),2006,20(6):487-489. 被引量:4
  • 4钱俐,茅国新,沈浮,李梅.多西紫杉醇联合氟尿嘧啶及顺铂治疗晚期胃癌[J].肿瘤防治研究,2007,34(7):526-527. 被引量:8
  • 5Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985 [J]. Int J Cancer, 1993,54(4) :594-606.
  • 6Parkin DM, Bray FI, Devesa SS Cancer burden in the year 2000 [J] The global picture. Eur J Cancer, 2001,37(Suppl 8) : S4-S66.
  • 7Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce disparities in different geographic regions of the world [J]. J Clin Oncol, 2006,24(14) :2137-2150.
  • 8Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer [J]. Br J Cancer,1995,71(3):587-591.
  • 9Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5- fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer [J]. Cancer, 1993,72(1):37-41.
  • 10Schethauer W, Kornek G, Zeh B. Palliative chemotherapy vs supportive care in patients with metastatic gastric cancer: a randomized trial [C]. Second International Conference on Biology, Prevention and Treatment of Gastrointestinal malignancies. Koln, 1995 : 65.

共引文献116

同被引文献39

引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部